ABSTRACT
Background Lassa fever is a fulminant viral illness associated with high in-hospital mortality. This disease constitutes a serious public health concern in West Africa, in particular Nigeria and the Mano River Union region (Guinea, Liberia, and Sierra Leone). In Sierra Leone, continuous monitoring of critically ill patients is hindered by a lack of equipment and personnel.
Methods We used wearable biosensor devices to remotely monitor hospitalized individuals with acute Lassa fever in order to describe vital sign trends that may be associated with clinical outcome and to evaluate the feasibility of this approach in a resource-limited setting.
Results The case fatality rate among participants (n=8) was 62.5%, with a median time from hospital admission to death of 2 days. Our results show that individuals who died (n=5) had higher mean heart rate (126 beats per minute) and respiratory rate (29 breaths per minute), as well as lower mean heart rate variability (10 ms), compared to those that survived (63 beats per minute, 22 breaths per minute, and 59 ms, respectively). Non-survivors also spent a greater proportion of their monitoring period in the age-specific tachycardia range (45.8%) compared to survivors (1.7%).
Conclusions Although real-time monitoring of vital signs using wearable biosensors may have the potential to identify decompensations earlier than traditional bedside vital sign collection in a resource-limited setting, technical improvements are still needed to enable widespread use of this tool, for both clinical and research purposes.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by NIH grant U01AI151812.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by research ethics boards at Tulane University (IRB #140674) as well as the Sierra Leone Ethics and Scientific Review Committee.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
